Hygeia Healthcare Holdings Co., Ltd. (6078) AI Stock Analysis

• Market Cap: HK$8.40B
• Dividend Yield: N/A
• Average Volume (3M): 7.15M
• Price to Earnings (P/E): 17.1
• Beta (1Y): 1.61
• Revenue Growth: -13.92%
• EPS Growth: -36.32%
• Country: HK
• Employees: 8,169
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.47
• Shares Outstanding: 618,499,000
• 10 Day Avg. Volume: 3,556,037
• 30 Day Avg. Volume: 7,151,771
• PEG Ratio: -1.17
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 91.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: HK$14.50 ▲(14.26% Upside)

Hygeia Healthcare's overall stock score is driven by strong financial performance, particularly in revenue growth and profitability, despite concerns over cash flow generation. Technical analysis indicates bearish momentum, and valuation is moderate with no dividend yield. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Robust gross profit margin

A 29.36% gross margin signals durable pricing power and effective cost control in core medical services and product lines. Sustained gross margin supports reinvestment in facilities and services, cushioning operating profit against demand fluctuations over months.

Diversified healthcare business model

A multi‑pillar model—patient services across hospitals/clinics plus product development and distribution—reduces single-market risk. Diversified revenue streams (services, devices, pharmaceuticals, insurer and government contracts) increase structural resilience and cash flow stability.

Manageable leverage and solid equity base

A 0.42 debt/equity and ~61% equity ratio indicate a conservative capital structure, providing financial flexibility to fund growth or weather shocks. Solid ROE (~9%) shows reasonable capital efficiency, supporting long-term investment capacity without excessive leverage.

Negative Factors

Null free cash flow in 2024

Zero free cash flow is a structural concern for funding capex, servicing debt, and financing expansion without external capital. Persistent weak FCF can force higher borrowing, dilute shareholders, or constrain investments that drive medium‑term growth and operational improvements.

Increasing total debt could pose risks

Although current leverage is manageable, a trend of rising debt reduces financial flexibility and raises interest exposure. Over 2–6 months this can increase fixed costs, limit strategic options, and amplify vulnerability to demand or reimbursement shocks in healthcare.

Net profit margin compression

A declining net margin, despite healthy gross margin, suggests higher operating costs, financing expenses, or nonoperating items. Sustained margin pressure would erode retained earnings and reinvestment capacity, weakening long‑term profitability and returns.

Hygeia Healthcare Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Hygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Hygeia Healthcare generates revenue through multiple key streams, including patient services, which encompass hospital admissions, outpatient treatments, and specialized medical procedures. The company also earns income from the sale of healthcare products such as medical devices and pharmaceuticals. Significant partnerships with insurance providers enhance its revenue by ensuring a steady flow of patients covered under various health plans. Furthermore, Hygeia may engage in government contracts for public health initiatives, further diversifying its income sources. The combination of these revenue streams, along with a focus on expanding its service offerings and improving operational efficiencies, contributes to the company's overall financial performance.

Hygeia Healthcare Holdings Co., Ltd. Financial Statement Overview

Summary

Hygeia Healthcare shows strong revenue growth and profitability with a robust gross profit margin. The balance sheet is stable with manageable leverage, but the cash flow situation, particularly free cash flow generation, requires improvement to sustain long-term growth.

Income Statement

Hygeia Healthcare demonstrated strong revenue growth and profitability. The gross profit margin was robust at 29.36% for 2024, showing effective cost management. However, net profit margin decreased slightly to 13.45%, indicating some pressure on bottom-line profitability. Revenue grew by 9.06% from 2023 to 2024, showcasing continued expansion, but the slower growth compared to previous years may warrant monitoring.

Balance Sheet

The company's balance sheet reflects a healthy equity position, with a debt-to-equity ratio of 0.42 in 2024, indicating manageable leverage. Return on equity was solid at 8.99%, though slightly down from the previous year, suggesting efficient use of equity capital. The equity ratio is healthy at 60.88%, highlighting financial stability. However, increasing total debt levels could pose future risks.

Cash Flow

Cash flow analysis reveals challenges with free cash flow generation, as free cash flow was null in 2024. The operating cash flow to net income ratio is unavailable, suggesting a need for better alignment of operating cash flows to net income. The company must focus on enhancing cash flow from operations to support ongoing investments and debt obligations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.06B	4.45B	4.08B	3.20B	2.32B	1.40B
Gross Profit	827.26M	1.31B	1.29B	1.02B	744.66M	471.96M
EBITDA	588.77M	999.10M	1.11B	868.43M	623.67M	385.36M
Net Income	337.22M	598.26M	682.93M	476.78M	441.46M	170.09M
Balance Sheet
Total Assets	10.94B	10.93B	10.73B	7.24B	6.69B	4.70B
Cash, Cash Equivalents and Short-Term Investments	672.38M	651.59M	755.89M	884.71M	1.10B	2.58B
Total Debt	2.65B	2.79B	2.72B	1.29B	1.23B	2.48M
Total Liabilities	4.04B	4.25B	4.48B	2.30B	2.21B	359.93M
Stockholders Equity	6.88B	6.65B	6.23B	4.93B	4.46B	4.27B
Cash Flow
Free Cash Flow	44.76M	92.02M	-157.98M	92.26M	-236.84M	-25.77M
Operating Cash Flow	178.17M	707.13M	782.84M	685.38M	426.25M	296.13M
Investing Cash Flow	-24.67M	-671.09M	-2.86B	-372.06M	-850.85M	-2.48B
Financing Cash Flow	-87.30M	-216.56M	1.78B	-154.21M	754.50M	2.17B

Hygeia Healthcare Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6078, the sentiment is Positive. The current price of 12.69 is below the 20-day moving average (MA) of 13.11, below the 50-day MA of 12.78, and below the 200-day MA of 14.37, indicating a neutral trend. The MACD of 0.36 indicates Negative momentum. The RSI at 60.36 is Neutral, neither overbought nor oversold. The STOCH value of 69.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6078.

Hygeia Healthcare Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3689	71 Outperform	HK$601.91M	7.29	5.33%	9.14%	0.47%	50.46%
1526	66 Neutral	HK$1.57B	5.42	20.47%	4.37%	-3.56%	-17.45%
2273	66 Neutral	HK$7.45B	20.16	14.86%	2.61%	16.41%	32.97%
2373	66 Neutral	HK$6.65B	21.23	31.23%	1.97%	28.53%	22.34%
6078	62 Neutral	HK$8.40B	17.08	6.78%	―	-13.92%	-36.32%
1951	55 Neutral	HK$6.75B	-6.48	-9.67%	2.38%	-8.56%	-403.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Hygeia Healthcare Holdings Co., Ltd. Corporate Events

Hygeia Healthcare Announces Share Repurchase Plan

Hygeia Healthcare Holdings Co., Ltd. announced a proposed on-market share repurchase, intending to buy back up to 61,849,900 shares, equivalent to 10% of its total issued shares. The company believes the current trading price undervalues its intrinsic worth and business prospects, and the repurchase is aimed at enhancing shareholder value and demonstrating confidence in its financial position.

The most recent analyst rating on (HK:6078) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.